Octreotide is a somatostatin analog that inhibits growth hormone release showing higher potency than natural @entity1943 so it has proved to be effective in @entity2012 treatment. The objective of present study was to establish the effects of octreotide @entity8800 ) preparation in @entity1 with active @entity2012 . The following parameters were assessed: clinical response, safety of medication, GH and @entity442 serum concentrations and @entity977 size. Eleven @entity1 (6 @entity1 and 5 @entity1 ) range 41.4 years old with diagnosis of active @entity2012 were included. Octreotide was administered at 0.1 mg subcutaneusly dose three times daily for four weeks to test the drug tolerability. Afterwards @entity1 received octreotide LAR 20 mg intramuscularly separated by 28 days periods with an option to continue for 8 months. Basal average GH serum concentrations was 27.6 ng/mL. After 6 months treatment reduction to 5.03 +/- 5.38 ng/mL in 9 @entity1 (p < 0.001) was observed. Basal @entity442 average serum concentration was 889.55 +/- 167.29 ng/mL with a reduction value to 483.00 +/- 239.71 ng/mL in 9 of 11 @entity1 after 6 months treatment (p < 0.005). The drug was well tolerated with few adverse effects @entity294 , @entity11634 and @entity6123 were observed during the administration of subcutaneous octreotide in 18.2% of @entity1 . Two @entity1 had symptomatic @entity9279 that was successfully removed by surgery. Clinical symptoms improved and some of them dissapeared such as @entity10 and sweatings. @entity5 shrinkage was observed in 66.7% of cases. Monthly injections of 20 mg of octreotide LAR were effective to reduce GH and @entity442 levels in @entity1 with active @entity2012 accompanied by improvement of clinical symptoms and significant @entity5 size reduction.

Improvement of XXXX after octreotide LAR treatment.

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'men'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Tumor'] @entity294 :: ('MESH:D003967', 'Disease') :: ['Diarrhea'] @entity442 :: ('3479', 'Gene') :: ['IGF-1'] @entity8800 :: ('5792', 'Gene') :: ['LAR (long acting release'] @entity6123 :: ('MESH:D045602', 'Disease') :: ['steatorrhea'] @entity11634 :: ('MESH:D005414', 'Disease') :: ['flatulence'] @entity2012 :: ('MESH:D000172', 'Disease') :: ['acromegaly'] @entity977 :: ('MESH:D010911', 'Disease') :: ['pituitary tumor'] @entity1943 :: ('MESH:D013004', 'Chemical') :: ['somatostatin'] @entity10 :: ('MESH:D006261', 'Disease') :: ['headaches'] @entity9279 :: ('MESH:D020347', 'Disease') :: ['biliary lithiasis']
@entity2012 :: (MESH:D000172,Disease) :: ['acromegaly']
